

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



PD 117519

Item No. 28444

CAS Registry No.: 96392-15-3

Formal Name: N-[(1R)-2,3-dihydro-1H-inden-1-yl]-adenosine

Synonym: CI-947 MF: C₁₉H₂₁N₅O₄ FW: 383.4 **Purity:**

UV/Vis.: λ_{max} : 211, 273 nm

A solid Supplied as: -20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PD 117519 is supplied as a solid. A stock solution may be made by dissolving the PD 117519 in the solvent of choice, which should be purged with an inert gas. PD 117519 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PD 117519 in these solvents is approximately 0.1, 5, and 10 mg/ml, respectively.

PD 117519 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PD 117519 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PD 117519 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PD 117519 is an adenosine receptor agonist. It selectively binds to adenosine A_2 receptors (IC₅₀ = 30 μ M) over A_1 receptors (IC₅₀ = 810 μ M) in rat brain membranes. PD 117519 increases heart rate and decreases systolic blood pressure in normotensive dogs when administered at doses of 2 or 10 mg/kg.²

References

- 1. Steffen, R.P. Method of treating heart failure and medicaments therefor. Warner-Lambert Company. **4,693,996** (1987).
- 2. Enerson, B.E., Lin, A., Lu, B., et al. Acute drug-induced vascular injury in beagle dogs: Pathology and correlating genomic expression. Toxicol. Pathol. 34(1), 27-32 (2006).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 11/05/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM